Alecensa (alectinib) is now an option for patients with stage 1b to 3a ALK-positive NSCLC who have ... In another positive development for the lung cancer community, NICE has also given its ...

The "cell of origin" of the second most common lung cancer and the way that it becomes dominant in the lung have been ...

“I really can’t stress the importance of early detection enough,” he says. “Catching it early can literally add years and ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

Next week the American Lung Association in Minnesota will turn the Twin Cities turquoise to raise awareness about lung cancer, honor those impacted and encourage residents to take action to help end ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

In solid tumors, such as skin, lung, or bone and soft tissue cancer ... New Immune Boost Could Expand Access to Cancer Immunotherapy Apr. 11, 2025 — Researchers have found that tapping into the ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...